Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
G-MDSC (granulocytic MDSC)
MDSC (myeloid-derived suppressor cells)
cancer
immunotherapy
neutrophil (PMN)
subsets
tumor-associated neutrophils (TANs)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
05
2019
accepted:
28
08
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Neutrophils have been extensively described in the pathophysiology of autoimmune and infectious diseases. Accumulating evidence also suggests the important role of neutrophils in cancer progression through their interaction with cancer and immune cells in blood and in the tumor microenvironment (TME). Most studies have described neutrophils as key drivers of cancer progression, due to their involvement in various tumor promoting functions including proliferation, aggressiveness, and dissemination, as well as in immune suppression. However, such studies were focusing on late-stages of tumorigenesis, in which chronic inflammation had already developed. The role of tumor-associated neutrophils (TANs) at early stages of tumor development remains poorly described, though recent findings indicate that early-stage TANs may display anti-tumor properties. Beyond their role at tumor site, evidence supported by NLR retrospective studies and functional analyses suggest that blood neutrophils could also actively contribute to tumorigenesis. Hence, it appears that the phenotype and functions of neutrophils vary greatly during tumor progression, highlighting their heterogeneity. The origin of pro- or anti-tumor neutrophils is generally believed to arise following a change in cell state, from resting to activated. Moreover, the fate of neutrophils may also involve distinct differentiation programs yielding various subsets of pro or anti-tumor neutrophils. In this review, we will discuss the current knowledge on neutrophils heterogeneity across different tissues and their impact on tumorigenesis, as well as neutrophil-based therapeutic strategies that have shown promising results in pre-clinical studies, paving the way for the design of neutrophil-based next generation immunotherapy.
Identifiants
pubmed: 31616408
doi: 10.3389/fimmu.2019.02155
pmc: PMC6764113
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2155Informations de copyright
Copyright © 2019 Lecot, Sarabi, Pereira Abrantes, Mussard, Koenderman, Caux, Bendriss-Vermare and Michallet.
Références
Science. 2018 Sep 28;361(6409):
pubmed: 30262472
Sci Rep. 2018 Mar 6;8(1):4044
pubmed: 29511262
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Nature. 2019 May;569(7754):73-78
pubmed: 30996346
Int J Cancer. 2011 Nov 1;129(9):2183-93
pubmed: 21190185
Int J Cancer. 2016 Jul 15;139(2):446-56
pubmed: 26939802
J Clin Invest. 2014 Dec;124(12):5466-80
pubmed: 25384214
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Ann Pharmacother. 1996 Jul-Aug;30(7-8):858-64
pubmed: 8826571
Immunity. 2010 Nov 24;33(5):657-70
pubmed: 21094463
World J Surg Oncol. 2016 May 16;14:148
pubmed: 27184053
Eur J Cancer. 2018 Jan;89:56-63
pubmed: 29227818
Cell. 2016 Oct 20;167(3):829-842.e13
pubmed: 27745970
Blood. 2009 May 7;113(19):4711-9
pubmed: 19264920
J Immunother Cancer. 2018 Jul 16;6(1):74
pubmed: 30012216
J Leukoc Biol. 2011 Feb;89(2):311-7
pubmed: 21106641
Oncoimmunology. 2017 Jun 16;6(7):e1331807
pubmed: 28811975
Cell Rep. 2018 Jun 26;23(13):3946-3959.e6
pubmed: 29949776
J Immunol. 2005 May 1;174(9):5472-80
pubmed: 15843545
Ann Oncol. 2016 Sep;27(suppl 5):v111-v118
pubmed: 27664247
J Immunol. 2014 Apr 15;192(8):3470-3
pubmed: 24639346
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460
pubmed: 28900008
Clin Cancer Res. 2019 Mar 15;25(6):1957-1969
pubmed: 30482778
Cancer Chemother Pharmacol. 2016 Apr;77(4):703-12
pubmed: 26886017
Immunol Invest. 2012;41(6-7):614-34
pubmed: 23017138
Cancer Res. 2016 Mar 15;76(6):1367-80
pubmed: 26759232
Int J Hematol. 2018 Apr;107(4):451-459
pubmed: 29103138
Nature. 2014 Nov 6;515(7525):134-7
pubmed: 25156255
J Immunol. 2012 Nov 1;189(9):4674-83
pubmed: 23028051
Pigment Cell Melanoma Res. 2011 Apr;24(2):366-76
pubmed: 21029397
Oncoimmunology. 2017 Aug 16;6(11):e1356965
pubmed: 29147615
EBioMedicine. 2017 Apr;18:56-61
pubmed: 28356222
Sci Rep. 2019 Feb 6;9(1):1509
pubmed: 30728369
Cancer Sci. 2011 Sep;102(9):1724-33
pubmed: 21599811
JCI Insight. 2019 Mar 7;4(5):null
pubmed: 30730851
Biomarkers. 2014 Jun;19(4):287-90
pubmed: 24731052
JCI Insight. 2019 Jan 24;4(2):null
pubmed: 30674719
Clin Colorectal Cancer. 2006 Nov;6(4):297-304
pubmed: 17241514
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
pubmed: 21081700
PLoS One. 2011;6(11):e27690
pubmed: 22110722
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
PLoS One. 2013 May 29;8(5):e64814
pubmed: 23734221
Asia Pac J Clin Oncol. 2017 Oct;13(5):e189-e194
pubmed: 25359280
J Thorac Oncol. 2017 Aug;12(8):1268-1279
pubmed: 28483607
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
J Exp Clin Cancer Res. 2015 Oct 26;34:129
pubmed: 26503598
Biomarkers. 2015;20(4):232-9
pubmed: 26301881
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1186-92
pubmed: 15498828
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
PLoS One. 2017 Dec 6;12(12):e0188799
pubmed: 29211768
Cancer Immunol Immunother. 2018 Jul;67(7):1031-1040
pubmed: 29541787
Sci Transl Med. 2016 Oct 19;8(361):361ra138
pubmed: 27798263
J Immunol. 2014 Aug 15;193(4):1954-65
pubmed: 25024378
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cancer Cell. 2016 Oct 10;30(4):533-547
pubmed: 27728804
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11300-11305
pubmed: 27651484
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Cell. 2018 Oct 8;34(4):561-578.e6
pubmed: 30300579
Cancer Res. 2001 Jun 15;61(12):4756-60
pubmed: 11406548
Clin Chem Lab Med. 2001 May;39(5):374-9
pubmed: 11434384
J Clin Invest. 2013 Jul 1;:null
pubmed: 23863628
Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2078-87
pubmed: 27470511
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Evid Based Complement Alternat Med. 2013;2013:423129
pubmed: 23737831
ESMO Open. 2016 Mar 7;1(2):e000038
pubmed: 27843594
Theranostics. 2018 Nov 12;8(21):5842-5854
pubmed: 30613266
J Exp Med. 2013 Oct 21;210(11):2321-36
pubmed: 24081949
Nat Med. 2010 Feb;16(2):219-23
pubmed: 20081861
Blood. 2003 Mar 15;101(6):2219-26
pubmed: 12406904
Tumori. 2018 Dec;104(6):415-422
pubmed: 29714669
Int Urol Nephrol. 2014 Aug;46(8):1531-5
pubmed: 24526335
Front Immunol. 2017 Apr 19;8:443
pubmed: 28458672
Oncotarget. 2016 Dec 20;7(51):85185-85195
pubmed: 27835905
Cancer Cell. 2016 Jul 11;30(1):120-135
pubmed: 27374224
Tumori. 2017 Sep 18;103(5):443-448
pubmed: 28731495
J Clin Invest. 2010 Jul;120(7):2423-31
pubmed: 20516641
Curr Cancer Drug Targets. 2012 Nov 1;12(9):1233-43
pubmed: 22873218
Br J Cancer. 2013 May 28;108(10):2116-22
pubmed: 23591202
Oncotarget. 2017 Jan 10;8(2):2329-2341
pubmed: 27911876
J Biol Chem. 2012 Jul 20;287(30):25139-50
pubmed: 22679018
Mod Pathol. 2002 Aug;15(8):831-7
pubmed: 12181268
Cancer Immunol Immunother. 2017 Aug;66(8):979-988
pubmed: 28214929
J Immunol. 2014 Mar 1;192(5):2374-83
pubmed: 24493821
Front Immunol. 2018 Mar 02;9:398
pubmed: 29552012
Nat Med. 2014 Dec;20(12):1464-71
pubmed: 25362254
Nature. 2015 Jun 18;522(7556):349-53
pubmed: 25985180
Int J Urol. 1996 Mar;3(2):152-4
pubmed: 8689512
Nature. 2019 Feb;566(7745):553-557
pubmed: 30728496
Cancer Res. 2013 Jan 15;73(2):571-82
pubmed: 23204236
Clin Cancer Res. 2017 Jun 15;23(12):2942-2950
pubmed: 27965309
J Clin Oncol. 2003 Sep 15;21(18):3462-8
pubmed: 12972521
Gynecol Oncol. 2017 Jun;145(3):469-475
pubmed: 28552395
Cancer Immunol Res. 2015 Nov;3(11):1236-47
pubmed: 26025381
Surg Oncol. 2014 Mar;23(1):31-9
pubmed: 24378193
Clin Cancer Res. 2019 May 15;25(10):3164-3175
pubmed: 30674502
Obstet Gynecol. 2004 Nov;104(5 Pt 1):1086-8
pubmed: 15516405
Clin Cancer Res. 2009 Mar 15;15(6):2148-57
pubmed: 19276286
Nat Med. 2013 Jan;19(1):57-64
pubmed: 23202296
Clin Pharmacol Ther. 2010 Apr;87(4):401-6
pubmed: 20200512
Br J Cancer. 2004 Nov 29;91(11):1970-6
pubmed: 15545974
Immunity. 2003 Jul;19(1):131-44
pubmed: 12871645
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Neoplasia. 2012 Aug;14(8):709-18
pubmed: 22952424
Immunity. 2017 Oct 17;47(4):789-802.e9
pubmed: 29045907
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Cancer Discov. 2017 Jul;7(7):694-703
pubmed: 28288993
Int Immunopharmacol. 2011 Jul;11(7):856-61
pubmed: 21315783
Blood. 2002 Dec 15;100(13):4574-80
pubmed: 12393717
Cytokine Growth Factor Rev. 2014 Aug;25(4):355-67
pubmed: 25131807
Hinyokika Kiyo. 2002 Aug;48(8):495-8
pubmed: 12243077
Ann Oncol. 2018 Apr 1;29(4):924-930
pubmed: 29324972
Blood. 2017 Mar 9;129(10):1343-1356
pubmed: 28053192
Med Oncol. 2014 Nov;31(11):264
pubmed: 25273866
Nat Med. 2005 Dec;11(12):1314-21
pubmed: 16288283
Front Immunol. 2018 Jun 28;9:1474
pubmed: 30002656
Int J Cancer. 2017 May 15;140(10):2321-2330
pubmed: 28177522
Cell Death Dis. 2014 Dec 11;5:e1563
pubmed: 25501824
Oncogene. 2016 Sep 22;35(38):4957-72
pubmed: 27109103
Cell Rep. 2015 Feb 3;10(4):562-73
pubmed: 25620698
PLoS One. 2012;7(1):e30806
pubmed: 22295111
Cancer Res. 2010 Jul 15;70(14):6071-82
pubmed: 20610626
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):7022-7027
pubmed: 29915060
Clin Exp Metastasis. 2018 Apr;35(4):255-267
pubmed: 29968171
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Immunity. 2003 Oct;19(4):583-93
pubmed: 14563322
Immunity. 2018 Feb 20;48(2):364-379.e8
pubmed: 29466759
Cytokine. 2008 Jun;42(3):277-88
pubmed: 18400509
J Clin Oncol. 2009 Oct 1;27(28):4709-17
pubmed: 19720929
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Onco Targets Ther. 2017 Aug 04;10:3917-3924
pubmed: 28831266
Support Care Cancer. 2012 Aug;20(8):1869-74
pubmed: 21986674
Cancer Cell. 2015 Dec 14;28(6):785-799
pubmed: 26678340
Gastroenterology. 2016 Jun;150(7):1646-1658.e17
pubmed: 26924089
Cell. 2019 Jul 11;178(2):346-360.e24
pubmed: 31257026
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
Nat Med. 2007 Apr;13(4):463-9
pubmed: 17384648
Cancer Res. 2010 May 1;70(9):3526-36
pubmed: 20406969
Immunol Rev. 2015 Nov;268(1):123-38
pubmed: 26497517
Cancer Med. 2017 Jun;6(6):1424-1436
pubmed: 28544785
Oncoimmunology. 2015 Jan 07;4(3):e989764
pubmed: 25949902
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Int J Mol Sci. 2018 Jun 19;19(6):null
pubmed: 29921770
Circulation. 2003 Jun 10;107(22):2829-36
pubmed: 12771009
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
Clin Cancer Res. 2017 Mar 15;23(6):1575-1585
pubmed: 27620275
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
Med Oncol. 2014 Jun;31(6):969
pubmed: 24793745
PLoS One. 2012;7(12):e50035
pubmed: 23227158
Medicine (Baltimore). 2018 Jul;97(30):e11648
pubmed: 30045314
Gut. 2017 Nov;66(11):1900-1911
pubmed: 28274999
Curr Oncol. 2018 Apr;25(2):e113-e119
pubmed: 29719435
J Clin Invest. 2010 Apr;120(4):1151-64
pubmed: 20237412
Cancer Res. 2009 Feb 15;69(4):1553-60
pubmed: 19201693
Science. 1994 Jul 29;265(5172):682-4
pubmed: 8036519
EMBO Mol Med. 2013 Aug;5(8):1213-26
pubmed: 23918228
Cell Rep. 2018 Aug 28;24(9):2329-2341.e8
pubmed: 30157427
Science. 2017 Dec 1;358(6367):
pubmed: 29191879
Cancer Res. 2012 Aug 15;72(16):3919-27
pubmed: 22751466
Cell Rep. 2017 Dec 12;21(11):3190-3204
pubmed: 29241546
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Immunother Cancer. 2017 Dec 19;5(1):101
pubmed: 29254508
Clin Cancer Res. 2017 Jul 15;23(14):3847-3858
pubmed: 28108544
J Immunol. 1994 Jan 15;152(2):774-82
pubmed: 7506734
Clin Cancer Res. 2006 Nov 15;12(22):6765-71
pubmed: 17121897
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Br J Cancer. 2011 Apr 12;104(8):1288-95
pubmed: 21448173
J Clin Invest. 2012 Jan;122(1):327-36
pubmed: 22156198
PLoS One. 2016 May 02;11(5):e0154484
pubmed: 27136460
Nat Commun. 2017 Nov 10;8(1):1404
pubmed: 29123081
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Autophagy. 2012 Nov;8(11):1557-76
pubmed: 22874569
Hum Pathol. 2017 Oct;68:193-202
pubmed: 28882699
Int J Clin Oncol. 2018 Apr;23(2):368-374
pubmed: 29086877
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Cancer Lett. 2009 May 8;277(1):91-100
pubmed: 19138817
Cancer. 2012 May 1;118(9):2476-85
pubmed: 21953023
Lung Cancer. 2007 Apr;56(1):25-33
pubmed: 17175059
J Clin Invest. 2018 Aug 1;128(8):3425-3438
pubmed: 29771686
Scand J Immunol. 1999 Oct;50(4):433-9
pubmed: 10520185
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Chem Biol. 2007 Nov;14(11):1221-31
pubmed: 18022561
Clin Chem Lab Med. 2002 Apr;40(4):351-5
pubmed: 12059074
PLoS One. 2018 Oct 10;13(10):e0204490
pubmed: 30304046
Oncoimmunology. 2017 Jun 30;6(10):e1344804
pubmed: 29123954
Sci Rep. 2018 Jun 21;8(1):9453
pubmed: 29930287
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
PLoS One. 2018 Apr 6;13(4):e0195042
pubmed: 29624591
J Clin Invest. 2008 Oct;118(10):3367-77
pubmed: 18776941
Sci Rep. 2018 Nov 9;8(1):16611
pubmed: 30413724
Eur Urol. 2016 Aug;70(2):358-64
pubmed: 26924770
Mol Cancer. 2013 Dec 09;12(1):154
pubmed: 24321240
Blood. 1997 Dec 1;90(11):4485-92
pubmed: 9373259
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Clin Chem Lab Med. 2007;45(1):30-4
pubmed: 17243911
Nat Commun. 2017 Apr 06;8:14979
pubmed: 28382931
PLoS One. 2018 Jun 28;13(6):e0199740
pubmed: 29953504
Oncoimmunology. 2016 Sep 13;5(11):e1232221
pubmed: 27999744
Br J Cancer. 2015 Jun 9;112(12):1904-10
pubmed: 26010413
Cancer Res. 2019 May 15;79(10):2669-2683
pubmed: 30877108
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Cancer Immunol Res. 2017 Mar;5(3):257-268
pubmed: 28108629